Sugi Predict

Sugi Predict / Compounds / SCHEMBL7920736

SCHEMBL7920736

SCHEMBL7920736

Cc1cnc2sc(C)cc2c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 2/20 0.45
▸ CCR5 P51681 2/20 0.45
▸ CCR8 P51685 2/20 0.45
▸ CYP1A2 P05177 1/20 0.41
▸ IKBKB O14920 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.36
▸ PSMD14 O00487 1/20 0.36
▸ COPS5 Q92905 1/20 0.36
▸ NOS1 P29475 2/20 0.35
▸ NOS3 P29474 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ KAT2B Q92831 2/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ PLAU P00749 1/20 0.31
▸ ADRA2A P08913 1/20 0.31
▸ ADRA2B P18089 1/20 0.31
▸ ADRA2C P18825 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8291145 0.79 ALDH1A1 (0.34) KDM4ENOS1BACE1
SCHEMBL20290100 0.79 CCR1 (0.42) CCR1CCR5CCR8CYP1A2IKBKB
SCHEMBL29808187 0.72 MAPK1 (0.35) —
SCHEMBL6674194 0.72 MAPK1 (0.35) —
SCHEMBL23846490 0.72 IKBKB (0.51) CCR1CCR5CCR8IKBKBKDM4E
SCHEMBL14232405 0.70 IKBKB (0.53) CCR1CCR5CCR8CYP1A2IKBKB
SCHEMBL14907175 0.70 NOS1 (0.32) CYP1A2NOS1
SCHEMBL14707165 0.70 CCR1 (0.45) CCR1CCR5CCR8CYP1A2IKBKB
SCHEMBL7921134 0.68 SMN1; SMN2 (0.43) CCR1CCR5CCR8CYP1A2IKBKB
SCHEMBL12434 0.68 CYP2A6 (0.55) CCR1CCR5CCR8KDM4EPSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858904-B2 Process for preparing large size isoxazoline particles INTERVET INC. (JE) 2024-01-02 — — US disclosed
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2023-07-25 — — US disclosed
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2023-07-25 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
EP-3426653-B1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2021-12-15 — — EP disclosed
WO-2020225143-A1 INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF INTERVET INTERNATIONAL B.V. (NL) 2020-11-12 — — WO disclosed
US-20200299305-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA 2020-09-24 — — US disclosed
US-20190071450-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2019-03-07 — — US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 — — US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 — — US disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 — — US disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
WO-2011136385-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-03 — — WO disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
WO-2004014384-A2 CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071450-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY SNCA, PARK7, NLN CCR1 4837/4885CCR5 4507/4885CCR8 4812/4885
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB CCR1 1872/4885CCR5 1490/4885CCR8 3179/4885
US-11858904-B2 Process for preparing large size isoxazoline particles PDE8A, RPS4X, MRPS27 CCR1 4258/4885CCR5 3050/4885CCR8 3991/4885
US-20200299305-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY SNCA, PARK7, NLN CCR1 4837/4885CCR5 4507/4885CCR8 4812/4885
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB CCR1 2213/4885CCR5 1519/4885CCR8 3336/4885
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use UCHL1, ADRM1, CRBN CCR1 4696/4885CCR5 4768/4885CCR8 4669/4885
US-20120142714-A1 BICYCLIC COMPOUND ACACA, ACACB, FABP4 CCR1 2289/4885CCR5 3185/4885CCR8 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.